Altimmune, Inc. (NASDAQ:ALT) Given Consensus Rating of "Moderate Buy" by Analysts

Key Points

• Altimmune, Inc. has received a consensus rating of "Moderate Buy" from analysts, with five buy ratings, one hold rating, and one sell rating.
• The company's stock is currently trading at $3.64, with a one-year price target averaging $17.40 among analysts.
• Altimmune recently reported better-than-expected earnings, with an EPS of ($0.27), surpassing the consensus estimate of ($0.32).

Altimmune, Inc. (NASDAQ:ALT - Get Free Report) has been given an average recommendation of "Moderate Buy" by the seven analysts that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $17.40.

Several research analysts have recently issued reports on ALT shares. JMP Securities cut their target price on shares of Altimmune from $25.00 to $15.00 and set a "market outperform" rating on the stock in a report on Thursday, July 10th. HC Wainwright reaffirmed a "buy" rating and issued a $12.00 price target on shares of Altimmune in a research note on Wednesday, August 13th. William Blair reaffirmed a "market perform" rating on shares of Altimmune in a research note on Friday, June 27th. B. Riley dropped their price target on Altimmune from $20.00 to $18.00 and set a "buy" rating for the company in a research note on Wednesday, August 13th. Finally, UBS Group dropped their price target on Altimmune from $26.00 to $24.00 and set a "buy" rating for the company in a research note on Wednesday, August 13th.

Altimmune Stock Down 1.4%

Shares of Altimmune stock opened at $3.64 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 20.44 and a current ratio of 20.44. Altimmune has a 52-week low of $2.90 and a 52-week high of $11.16. The stock has a market capitalization of $321.26 million, a price-to-earnings ratio of -3.08 and a beta of 0.18. The company's 50 day moving average price is $3.83 and its 200-day moving average price is $4.88.

Altimmune (NASDAQ:ALT - Get Free Report) last issued its earnings results on Tuesday, August 12th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.05. Altimmune had a negative net margin of 438,730.03% and a negative return on equity of 62.63%. The firm had revenue of $0.01 million for the quarter, compared to analysts' expectations of $0.00 million. Equities research analysts forecast that Altimmune will post -1.35 EPS for the current year.

Institutional Trading of Altimmune

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ALT. Federated Hermes Inc. lifted its stake in Altimmune by 387.7% in the second quarter. Federated Hermes Inc. now owns 915,458 shares of the company's stock worth $3,543,000 after acquiring an additional 727,731 shares during the period. Bank of America Corp DE lifted its position in Altimmune by 155.2% during the second quarter. Bank of America Corp DE now owns 716,019 shares of the company's stock valued at $2,771,000 after buying an additional 435,467 shares during the period. RFG Advisory LLC purchased a new position in Altimmune during the first quarter valued at $1,622,000. Nuveen LLC purchased a new position in Altimmune during the first quarter valued at $1,304,000. Finally, Caitong International Asset Management Co. Ltd lifted its position in Altimmune by 25,474.2% during the second quarter. Caitong International Asset Management Co. Ltd now owns 239,630 shares of the company's stock valued at $927,000 after buying an additional 238,693 shares during the period. Hedge funds and other institutional investors own 78.05% of the company's stock.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.